On January 9, 2026, CG Oncology announced an expedited timeline for topline data from its Phase 3 PIVOT-006 clinical trial, targeting over 50,000 patients with intermediate-risk non-muscle invasive bladder cancer, expected in the first half of 2026. The trial is pivotal in assessing the treatment's efficacy and safety, supported by encouraging early results from previous studies showing strong event-free survival rates.